Phase II Randomized Study of Liposomal Irinotecan with S-1 vs. Liposomal Irinotecan with 5-Fluorouracil in Metastatic Pancreatic Cancer Post-Gemcitabine Therapy
- Trial ID
- 2023-509463-24-01
- Sponsor
- Amsterdam UMC Stichting
Register record, history and transparency: CTIS.eu
Trial statistics
Diseases & Conditions
Objectives
The primary objective of this study is to determine the **progression-free survival (PFS)** benefit of nal-IRI combined with S-1, compared with nal-IRI combined with 5-FU/LV, in subjects pre-treated with gemcitabine-based chemotherapy for metastatic pancreatic ductal adenocarcinoma, or those who experienced progression within 6 months of adjuvant gemcitabine treatment. This objective is clinically relevant as it aims to identify a more effective second-line treatment option for patients with metastatic pancreatic cancer, potentially improving their disease management and outcomes.
Secondary objectives include:
- To determine the overall survival (OS) benefit of nal-IRI combined with S-1, compared with nal-IRI combined with 5-FU/LV.
- To determine the response rate according to RECIST 1.1 of the treatment combinations.
- To determine the adverse events according to NCI CTC version 4.0.
- To determine the Quality of Life (QoL) benefit of the treatment combinations.
- To assess the expression of relative abundance of stroma in metastatic tumor tissue and stromal markers, including ADAM12, as predictors of response to treatment and survival.
- To explore, by imaging, the effects of the treatment combination on tumor vascularity and stromal density.
- To explore changes in circulating tumor DNA (ctDNA).
Participants
The clinical trial involves participants diagnosed with **metastatic pancreatic cancer**, specifically those with histologically or cytologically confirmed adenocarcinoma of the pancreas. The study population includes both male and female subjects aged 18 years and older. Participants must have documented metastatic disease according to RECIST 1.1 and have been previously treated with gemcitabine-based chemotherapy or experienced progression within six months of adjuvant gemcitabine treatment. The trial does not include a vulnerable population. Participants are required to have adequate hepatic, renal, and hematological function. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet or physical activity.
Plans and Procedures
The clinical trial is a **randomized**, phase II study designed to evaluate the efficacy of second-line treatment regimens in patients with **metastatic pancreatic cancer** who have previously been treated with gemcitabine-based chemotherapy. The trial employs a **double-blind** and **controlled** methodology to ensure unbiased results. Participants will be randomly assigned to receive either a combination of liposomal **irinotecan** and S-1 or liposomal irinotecan and 5-fluorouracil. The primary objective is to assess the progression-free survival benefit of these treatment combinations. Secondary endpoints include overall survival, response rate according to RECIST 1.1, adverse events as per NCI CTC version 4.0, and quality of life measured by QLQ-C30.
The trial is expected to run until November 2031, with participant recruitment having commenced in January 2020. The study involves several key visits, beginning with an inclusion (screening) visit to confirm eligibility based on criteria such as age (≥ 18 years), confirmed adenocarcinoma of the pancreas, documented metastatic disease, and adequate hepatic, renal, and hematological function. Follow-up visits will be scheduled to monitor treatment response and adverse events, with the end-of-study visit marking the conclusion of the participant's involvement. The expected duration of participant involvement is contingent upon the treatment regimen, with a maximum treatment period of up to 4 months for certain regimens. Conditions that may lead to early termination from the study include disease progression, unacceptable toxicity, or withdrawal of consent by the participant.
Treatment
The clinical trial involves the administration of **Onivyde pegylated liposomal** 4.3 mg/ml concentrate for dispersion for infusion, which contains the active substance **irinotecan**. This pharmaceutical form is a concentrate for dispersion intended for **intravenous administration**. The maximum daily dose is 70 mg/m², with a total dose not exceeding 70 mg/m² over a treatment period of up to 4 weeks. The product is manufactured by Les Laboratoires Servier (Suresnes) and is chemically derived. Participant compliance with the dosing schedule will be monitored throughout the trial.
Another treatment used in the study is **Fluorouracil 50mg/ml Injection**, a solution for injection containing the active substance **fluorouracil**. This medication is also administered via **intravenous administration**. The maximum daily dose is 1252 mg/m², with a total dose limit of 2400 mg/m² over a treatment period of up to 2 weeks. The product is provided by Hospira UK Limited and is of chemical origin. Adherence to the dosing regimen will be closely observed to ensure participant compliance.
The trial also includes the use of **Teysuno 15 mg/4.35 mg/11.8 mg hard capsules**, which contain the active substances **tegafur, gimeracil, and oteracil**. These capsules are administered **orally**. The maximum daily dose is 140 mg, with a total dose not exceeding 1960 mg over a treatment period of up to 4 weeks. The product is manufactured by Nordic Group B.V. and is chemically derived. Compliance with the oral dosing schedule will be monitored to ensure accurate adherence by participants.
Efficacy
The efficacy of the clinical trial will be assessed primarily through the measurement of **progression-free survival (PFS)**. This endpoint will evaluate the duration during which patients with metastatic pancreatic ductal adenocarcinoma, who have been pre-treated with gemcitabine-based chemotherapy, remain free from disease progression. Secondary endpoints include overall survival, response rate according to RECIST 1.1 criteria, adverse events as per NCI CTC version 4.0, and quality of life assessed using the QLQ-C30 instrument.
Data collection for these endpoints will be conducted at specified intervals throughout the trial. The response rate will be determined using the RECIST 1.1 criteria, which provides a standardized approach to assess tumor response. Adverse events will be monitored and categorized according to the NCI CTC version 4.0 guidelines, ensuring a comprehensive evaluation of the safety profile of the treatment regimens. Quality of life will be measured using the QLQ-C30, a validated questionnaire designed to assess the overall well-being of cancer patients. These assessments will be conducted at various timepoints, including baseline, during treatment, and at the end of the treatment period, to provide a thorough analysis of the treatment's efficacy and impact on patients' quality of life.
Inclusion and Exclusion Criteria
Inclusion Criteria
- Able to understand and provide written informed consent
- ≥ 18 years of age
- Histologically or cytologically confirmed adenocarcinoma of pancreas
- Documented metastatic disease, according to RECIST 1.1.
- Previously treated with gemcitabine or gemcitabine containing therapy, or progression within 6 months of adjuvant gemcitabine based treatment
- Adequate hepatic (serum bilirubin total between 0-17 μmol/L, AST between 0-40 U/L, ALT between 0-34 U/L, renal (creatinine between 65-95 μmol/L) and hematological (hemoglobin between 7.5-10 mmol/L, platelets between 150-400 10E9/L, leukocytes between 4.0-10.5 10E9/L) function
Exclusion Criteria
- Serum total bilirubin ≥1.5 x ULN (biliary drainage is allowed for biliary obstruction)
- Severe renal impairment (CLcr ≤ 30 ml/min)
- Inadequate bone marrow reserves as evidenced by: a. ANC ≤ 1,5 x 10 9 /L; or b. Platelet count ≤ 100 x 10 9 /L;
- WHO/PS 2 or higher
- Any clinically significant disorder impacting the risk-benefit balance negatively per physician’s judgment
- Any clinically significant gastrointestinal disorder, including hepatic disorders, bleeding, inflammation, occlusion, or diarrhea > grade 1
- Severe arterial thromboembolic events (myocardial infarction, unstable angina pectoris, stroke) in last 6 months
- NYHA Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure. Or known abnormal ECG with clinically significant abnormal findings
- Active infection or an unexplained fever >38.5°C (excluding tumor fever), which in the physician’s opinion might compromise the patient’s health
- Current use or any use in last two weeks of strong CYP2A6- enzyme inhibitors, CYP3A-enzyme inducers/inhibitors and/or strong UGT1A inhibitors
- Known hypersensitivity to any of the components of liposomal irinotecan (Nal-IRI) other liposomal irinotecan formulations, irinotecan, fluoropyrimidines, or leucovorin.
- Hypersensitivity to any of the active substances (tegafur, gimeracil, and oteracil)
- Previous treatment with fluoropyrimidine therapy
- Known dihydropyrimidine dehydrogenase (DPD) deficiency
- Breast feeding, known pregnancy, positive serum pregnancy test or unwillingness to use a reliable method of birth control, during therapy and for 3 months following the last dose of liposomal irinotecan (Nal-IRI).
- or male patients: unwilling to use contraception during treatment and 4 months following last dose of Nal-IRI and 6 months after S-1
- Contraception required for 6 months following the last dose of S-1
- Treatment within 4 weeks with DPD inhibitors, including sorivudine or its chemically related analogues such as brivudine.
Trial Status by Country
| Country | Status | Start of Recruitment | Planned Patients |
|---|---|---|---|
Austria | Not Recruiting | 22 Jan 2020 | 5 |
Italy | Not Recruiting | 22 Jan 2020 | 80 |
The Netherlands | Not Recruiting | 22 Jan 2020 | — |
Spain | Not Recruiting | 22 Jan 2020 | 33 |
Netherlands | — | — | 28 |
Sites & Investigators
Investigational Products
Details about the medicinal products being studied in this clinical trial.
| Product Name | Role in Trial | Formulation | Administration | Max Daily Dose | Treatment Duration | EU MP Number |
|---|---|---|---|---|---|---|
Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion | Test | CONCENTRATE FOR DISPERSION FOR INFUSION | INTRAVENOUS ADMINISTRATION | 70 | 4 | PRD6811022 |
Fluorouracil 50mg/ml Injection. | Test | INJECTION | INTRAVENOUS ADMINISTRATION | 1252 | 2 | PRD1165361 |
Teysuno 15 mg/4.35 mg/11.8 mg hard capsules | Test | HARD CAPSULES | ORAL | 140 | 4 | PRD538059 |




